MedTrace Logo

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

NCT00002952 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-09-05

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cell to kill melanoma cells. Combining vaccine therapy with interleukin-12 may kill more melanoma cells.

PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy plus interleukin-12 in treating patients who have metastatic melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

MART-1 antigen

Melan-A peptide loaded PBMCs (sc, q3wk x 3)

BIOLOGICAL

recombinant MAGE-3.1 antigen

BIOLOGICAL

recombinant interleukin-12

rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Thomas F. Gajewski, MD, PhD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-01-31
Primary Completion
2002-08-31
Completion
2002-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002952 on ClinicalTrials.gov